Transarterial Chemoembolization of Metastatic Colorectal Carcinoma with Drug-Eluting Beads, Irinotecan (DEBIRI)‎ : Multi-Institutional Registry

Abstract EN

The purpose of this study was to evaluate the patient tolerance and efficacy of delivering locoregional chemotherapy to metastatic colorectal (MC) hepatic metastases via hepatic trans-arterial approach using irinotecan loaded drug eluting beads.

This open-label, multi-center, single arm study included 30 MC patients, who had failed first line therapy.

Of the 57 total embolization sessions, 12 (21% of sessions) were associated with adverse reactions during or after the treatment.

After a median followup of 9 months, response rates by modified RECIST were 75% at 3 months and 66% at 6 months.

Hepatic trans-arterial therapy using Irinotecan loaded DC BeadTM was safe and effective in the treatment of MCC as demonstrated by a minimal complication rate and acceptable tumor response.